Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
45.57
Dollar change
-1.18
Percentage change
-2.52
%
Index- P/E- EPS (ttm)-2.31 Insider Own10.24% Shs Outstand46.41M Perf Week-11.75%
Market Cap2.12B Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float41.85M Perf Month27.25%
Income-97.56M PEG- EPS next Q-0.23 Inst Own85.89% Short Float9.97% Perf Quarter3.85%
Sales0.00M P/S- EPS this Y-13.58% Inst Trans- Short Ratio4.39 Perf Half Y22.40%
Book/sh9.22 P/B4.94 EPS next Y21.89% ROA-27.69% Short Interest4.17M Perf Year41.43%
Cash/sh9.36 P/C4.87 EPS next 5Y- ROE-29.29% 52W Range25.57 - 75.02 Perf YTD11.80%
Dividend Est.- P/FCF- EPS past 5Y- ROI-22.51% 52W High-39.25% Beta-3.57
Dividend TTM- Quick Ratio19.05 Sales past 5Y0.00% Gross Margin- 52W Low78.22% ATR (14)3.80
Dividend Ex-Date- Current Ratio19.05 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)50.14 Volatility6.46% 11.61%
Employees93 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price83.10
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q25.68% Payout- Rel Volume0.75 Prev Close46.75
Sales Surprise- EPS Surprise0.72% Sales Q/Q- EarningsMay 09 AMC Avg Volume951.74K Price45.57
SMA20-1.22% SMA5010.91% SMA200-0.45% Trades Volume711,544 Change-2.52%
Date Action Analyst Rating Change Price Target Change
May-21-24Initiated JP Morgan Overweight $65
Apr-09-24Initiated Cantor Fitzgerald Overweight $65
Oct-19-23Initiated JMP Securities Mkt Outperform $90
Jul-27-23Initiated Piper Sandler Overweight $58
May-25-23Resumed Jefferies Buy $34 → $41
Feb-28-23Initiated SVB Securities Outperform $33
Feb-28-23Initiated Jefferies Buy $34
Feb-28-23Initiated Guggenheim Buy $50
Feb-28-23Initiated BMO Capital Markets Outperform $40
Jun-17-24 09:53AM
Jun-11-24 07:31PM
09:59AM
04:57AM
Jun-09-24 07:30AM
04:05PM Loading…
Jun-07-24 04:05PM
05:00AM
Jun-05-24 07:53PM
Jun-04-24 11:59AM
06:00AM
02:03AM
Jun-03-24 06:55PM
04:09PM
03:30PM
01:42PM
01:17PM Loading…
01:17PM
12:30PM
11:30AM
08:20AM
07:30AM
Jun-02-24 09:07AM
May-31-24 06:00AM
May-21-24 07:44AM
May-09-24 10:56PM
04:05PM
10:34AM
Apr-24-24 06:33AM
Mar-30-24 09:37AM
Mar-15-24 10:53AM
Mar-08-24 04:05PM
08:30AM Loading…
08:30AM
Jan-22-24 05:24AM
Dec-25-23 07:45AM
Dec-22-23 04:21PM
Dec-18-23 04:06PM
01:03PM
11:29AM
09:22AM
07:30AM
07:30AM
06:23AM
Dec-11-23 12:26PM
Nov-29-23 02:28PM
02:30AM
Nov-27-23 09:50AM
Nov-26-23 04:44PM
Nov-14-23 04:10PM
Nov-03-23 05:20AM
Oct-19-23 08:45AM
Oct-06-23 08:45AM
Oct-02-23 03:48PM
Sep-29-23 04:04PM
12:50PM
11:19AM
10:24AM
09:34AM
07:32AM
07:30AM
Aug-10-23 04:05PM
Aug-03-23 05:32PM
Jul-16-23 07:00AM
Jun-27-23 02:10PM
01:35PM
08:12AM
Jun-26-23 09:05PM
Jun-16-23 08:00AM
Jun-13-23 06:10AM
Jun-12-23 10:15AM
Jun-07-23 08:30AM
May-31-23 04:30PM
May-25-23 04:30PM
May-18-23 04:30PM
May-11-23 04:30PM
May-03-23 06:59AM
Mar-30-23 04:30PM
Feb-07-23 04:00PM
Feb-06-23 03:17PM
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 12 '24Option Exercise0.42150,00063,000793,346Jun 14 08:19 PM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Option Exercise0.34106,20036,108191,907Jun 05 07:38 PM